Huashen Technology Plans to relist and transfer 51% stake in Tibet Kangyu
September 6, 2025
Source: drugdu
149
On September 4th, Huashen Technology announced its intention to relist the 51% stake in its controlling subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., for a price of 42.5 million yuan. The company had already publicly listed the shares on the Southwest United Equity Exchange, but after the second round of listing announcements expired without a qualified prospective transferee, the company decided to relist the shares.
Comment: The failure to attract qualified potential transferees in the first two rounds of listing may mean that the market's valuation expectations for the equity sale are different from the company's, or that potential buyers have concerns about Kangyu Pharmaceutical's future development, industry competition situation, financial status, etc. The effect of re-listing will depend on the final transfer situation and market reaction.
https://finance.eastmoney.com/a/202509053505290366.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
